A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinuma

[Crohn2357]

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn s Disease (UNITI-2)
http://www.mayo.edu/research/clinical-trials/cts-20095685
This study is for patients with moderately to severely active Crohn’s Disease and have failed or your disease is not responding well enough to medicines that decrease the immune-response, specifically oral steroids (for example, prednisone) or methotrexate, or 6-mercaptopurine, or azathioprine.
http://www.mayo.edu/research/clinical-trials/cts-20026811
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects With Moderately to Severely Active Crohn s Disease
http://www.mayo.edu/research/clinical-trials/cts-20095686